{
  "abstract": "Introduction Endovascular treatment of intracranial aneurysms (IA) using endovascular implants has been challenged by incomplete occlusion in up to 50% of patients, including in the senior population, and large aneurysms. Photobiomodulation (PBM) is being successfully used to treat age-related dry macular degeneration and ulcers.Methods A highly flexible optical microfiber system was developed to deliver PBM through a commercially available 0.21’ microcatheter. Optimization of power, wavelength, and fluency was studied in tissue cultures and experimental settings. The PBM system was then tested in a rabbit elastase aneurysm model at various time points, including angiography, histology, and SEM.Results Control samples showed no significant endothelialization at 3 days and aneurysm patency. At 7-10 days, FD treated with PBM demonstrated complete aneurysm occlusion (RROC 1=85%) in samples and neck endothelialization, while control aneurysms remained patent in 5/10 subjects. Smooth muscle cell actin (SMA, non-specific for myoepithelial cells) and CD31 (platelet endothelial cell adhesion molecule 1) were found in large numbers in samples treated with PBM. At 30 days, angiography showed complete occlusion of the aneurysms treated with PBM and FD in all 7 rabbits (figure 1). At 180 days, PBM-treated and control animals showed a complete aneurysm occlusion except in one case with no FD coverage. Eleven patients received compassionate-use treatment with the Prometheus system combined with FD, achieving an 80% rate of complete or nearly complete aneurysm occlusion at a median follow-up of 3 months. PBM did not cause additional implant stenosis, edema of the surrounding brain tissue, or perforator occlusion.Conclusion Our preclinical and early clinical studies demonstrate that in situ PBM delivery is feasible and safe for patients treated with flow diverters. PBM could result in earlier and more complete aneurysm occlusion without increasing treatment risks. The technology represents a unique integration of regenerative medicine into endovascular therapy.Disclosures A. Wakhloo: 2; C; Stryker NV, JNJ Medtech, Philips. 4; C; Prometheus Therapeutics, Fluidbiomed. 5; C; Prometheus Therapeutics. G. Sluder: None. B. Lieber: 4; C; Prometheus Therapeutics. 5; C; Prometheus Therapeutics.Abstract O-072 Figure 1Abstract O-072 Figure 2",
  "authors": [
    {
      "affiliations": [
        "Radiology, Tufts University School of Medicine, Boston, MA"
      ],
      "name": "A Wakhloo"
    },
    {
      "affiliations": [
        "ponte vedra, FL"
      ],
      "name": "R Hanel"
    },
    {
      "affiliations": [
        "Neuroradiology, Paracelsus Medical University, Salzburg, Austria"
      ],
      "name": "M Killer-Oberpfalzer"
    },
    {
      "affiliations": [
        "Endovascular Neurosurgery, ENERI - Clínica la Sagrada Familia, Buenos Aires, Argentina"
      ],
      "name": "PN Lylyk"
    },
    {
      "affiliations": [
        "Insituto Medico ENERI-Clinica La Sagrada Familia, Bs As, Argentina"
      ],
      "name": "I Lylyk"
    },
    {
      "affiliations": [
        "Eneri-Clinica Adventista Belgrano, Belgrano, Argentina"
      ],
      "name": "P Lylyk"
    },
    {
      "affiliations": [
        "Radiology, University of Massachusetts, Worcester, MA"
      ],
      "name": "Y Uetake"
    },
    {
      "affiliations": [
        "Radiology, University of Massachusetts, Worcester, MA"
      ],
      "name": "G Sluder"
    },
    {
      "affiliations": [
        "Radiology, Tufts University School of Medicine, Boston, MA"
      ],
      "name": "B Lieber"
    }
  ],
  "title": "O-072 Endovascular photobiomodulation for accelerated and enhanced healing of intracranial aneurysms",
  "uid": "23c44bba-cd79-5feb-abf3-567915a6b6e8"
}